Wang Renfeng, Ye Fan, Zhen Qiang, Song Tieying, Tan Guoliang, Chu Weiwei, Zhang Yaxiao, Lv Baolei, Zhao Xiaojian, Liu Jiabao
Department of Thoracic Surgery, The First Hospital of Shijiazhuang, 36 Fanxi Road, Chang'an District, Shijiazhuang, 050011, Hebei Province, China.
Department of Hyperbaric Medicine, The Third Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
J Physiol Biochem. 2016 Jun;72(2):337-43. doi: 10.1007/s13105-016-0485-5. Epub 2016 Apr 15.
miR-148b has been found to be aberrantly expressed in various tumor types. It has recently been reported to be involved in regulating radioresistance in non-small cell lung cancer (NSCLC) cells. However, its expression level and association with radiosensitivity in human patient samples have not been investigated. Real-time PCR was used to evaluate the expression levels of miR-148b. Χ (2) test was performed to analyze the association between miR-148b expression levels and clinicopathological factors or radiosensitivity. Kaplan-Meier survival curve was constructed to estimate the overall survival (OS), and the differences in survival were compared using the log-rank test. Cox regression analysis was conducted to determine the prognostic value of miR-148b. The relative level of miR-148b was significantly decreased in NSCLC tissues compared with matched non-cancerous tissues (P < 0.0001), and it was higher in tissues of patients who are good responders compared to those who are poor responders to radiotherapy (P < 0.0001). Lower expression of miR-148b was positively associated with high tumor stage (P = 0.0407) and radioresistance (P = 0.0002), and it predicted poor survival in patients with (P = 0.0129) or without (P = 0.0094) radiotherapy treatment. miR-148b was an independent prognostic factor for NSCLC as demonstrated by Cox proportional hazards risk analysis. miR-148b may serve as a prognostic biomarker of poor survival and a novel predictor of response to radiotherapy treatment in NSCLC.
已发现miR-148b在多种肿瘤类型中异常表达。最近有报道称其参与调节非小细胞肺癌（NSCLC）细胞的放射抗性。然而，尚未研究其在人类患者样本中的表达水平及其与放射敏感性的关系。采用实时PCR评估miR-148b的表达水平。进行χ(2)检验以分析miR-148b表达水平与临床病理因素或放射敏感性之间的关联。构建Kaplan-Meier生存曲线以估计总生存期（OS），并使用对数秩检验比较生存差异。进行Cox回归分析以确定miR-148b的预后价值。与配对的非癌组织相比，NSCLC组织中miR-148b的相对水平显著降低（P < 0.0001），与放疗反应良好的患者组织相比，放疗反应不佳的患者组织中miR-148b水平更高（P < 0.0001）。miR-148b低表达与高肿瘤分期（P = 0.0407）和放射抗性（P = 0.0002）呈正相关，并且它预测接受（P = 0.0129）或未接受（P = 0.0094）放疗治疗的患者生存较差。Cox比例风险分析表明，miR-148b是NSCLC的独立预后因素。miR-148b可能作为生存不良的预后生物标志物以及NSCLC放疗反应的新型预测指标。
